Kobo Biotech (BOM:531541) Cash Flow for Dividends: ₹0.00 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531541 Kobo Biotech Ltd BOM:531541
13 GF Score
Price ₹8.23
View Full Analysis

What is Kobo Biotech Cash Flow for Dividends?

Kobo Biotech BOM:531541 -1.91% 13 Cash Flow for Dividends is ₹0.00 Mil as of Mar. 2025. GuruFocus rates BOM:531541 with a GF Score™ of 13/100.

Kobo Biotech's cash flow for dividends for the three months ended in Mar. 2025 was ₹0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Kobo Biotech Cash Flow for Dividends Related Terms

Kobo Biotech Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Kobo Biotech's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kobo Biotech Cash Flow for Dividends Chart

Kobo Biotech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kobo Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Mar25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:531541
13GF Score
Kobo Biotech Ltd BOM:531541
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kobo Biotech Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of ₹0.00 Mil mean?
Kobo Biotech (BOM:531541) has a Cash Flow for Dividends of ₹0.00 Mil as of Mar. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Kobo Biotech and its competitors.
Is Kobo Biotech's Cash Flow for Dividends too high?
Kobo Biotech's current Cash Flow for Dividends is ₹0.00 Mil. Overall, Kobo Biotech has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Kobo Biotech's Cash Flow for Dividends compare to ZTS?
Kobo Biotech's Cash Flow for Dividends of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Kobo Biotech and its competitors. Kobo Biotech's current Cash Flow for Dividends is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobo Biotech stock overvalued right now?
Kobo Biotech (BOM:531541) has a current Cash Flow for Dividends of ₹0.00 Mil. The current Cash Flow for Dividends is ₹0.00 Mil. Kobo Biotech's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Kobo Biotech (BOM:531541), the current Cash Flow for Dividends is ₹0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kobo Biotech Business Description

Address Saki Vihar Road, Unit 104, HYDE Park, Opposite Ansa Industrial Estate, Andheri (East), Mumbai, MH, IND, 400 072
Kobo Biotech Ltd is a pharmaceutical company. Its business comprises the manufacturing and sale of APIs (Active Pharmaceutical Ingredients) based on fermentation technology and Intermediates to pharmaceutical companies.
13GF Score

Get the complete analysis for BOM:531541

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8.23
Price